Description :
MyHep All (Sofosbuvir + Velpatasvir Tablets)
MyHep All is a fixed-dose combination antiviral medicine containing Sofosbuvir (400mg) and Velpatasvir (100mg). It is used in the treatment of chronic Hepatitis C virus (HCV) infection in adults of all major genotypes (1–6).
Sofosbuvir belongs to the class of nucleotide polymerase inhibitors, while Velpatasvir is an NS5A inhibitor. Together, they work by blocking different stages of the Hepatitis C virus replication process, helping to eliminate the infection from the body.
MyHep All is highly effective, often achieving sustained virologic response (SVR)—meaning the virus becomes undetectable—after a 12-week treatment course. It reduces liver damage, prevents complications such as cirrhosis and liver cancer, and improves overall liver health.
This medicine should be taken once daily, exactly as prescribed by a healthcare professional. It is not recommended without medical supervision, as dosage and duration depend on the patient’s health status and history of liver disease.
